Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib consolidation therapy in older adults with multiple myeloma
2005-004947-73Phase 3Completed
- Sponsor
- Janssen-Cilag
- Start
- Nov 2006
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of bortezomib in multiple myeloma (MM) (2 arms), sponsored by Janssen-Cilag. Primary endpoint: dose-limiting toxicity. Started Nov 2006; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2005-004947-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004947-73.